Serotype incidence and antibiotic susceptibility of Streptococcus pneumoniae causing invasive disease in Scotland, 1999-2002

被引:15
作者
Denham, BC
Clarke, SC
机构
[1] Scottish Meningococcus & Pneumococcus Reference L, Glasgow, Lanark, Scotland
[2] Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow, Lanark, Scotland
关键词
D O I
10.1099/jmm.0.45718-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Pneumococcal disease remains an important cause of invasive and non-invasive disease in Scotland and elsewhere. The Scottish Meningococcus and Pneumococcus Reference Laboratory receives isolates of Streptococcus pneumoniae from diagnostic laboratories around Scotland. Here, the serogroups/types and antibiotic-susceptibility patterns of invasive isolates received between 1999 and 2002 are described. There were a total of 1741 invasive isolates received, the most common serogroups/types being 14 (19.8%), 9 (10.2%), 6 (8.3%), 19 (7.9%), 23 (7.9%), 4 (6.5%), 8 (6.4%), 3 (5.7%), 1 (3.8%), 7 (3.8%) and 18 (3.4%). Importantly, serotypes 7 and 8 are not represented in the 7-, 9- and 11-valent pneumococcal conjugate polysaccharicle vaccines. There were 67 (3.8%) isolates considered penicillin non-susceptible, although no penicillin resistance (MIC >= 0.002 mg ml(-1)) was recorded. One hundred and ninety-four (11.1%) isolates, predominantly of serotype 14, were resistant to erythromycin, and 12 (0.7%) were resistant to ciprofloxacin. This information provides an important dataset that will prove essential prior to and during the implementation of pneumococcal conjugate vaccines in the UK.
引用
收藏
页码:327 / 331
页数:5
相关论文
共 13 条
[1]   Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands [J].
Bos, JM ;
Rümke, H ;
Welte, R ;
Postma, MJ .
CLINICAL THERAPEUTICS, 2003, 25 (10) :2614-2630
[2]  
CLARKE SC, 2001, SCIEH WEEKLY REPORT, V35, P2
[3]   Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction [J].
Gertz, RE ;
McEllistrem, MC ;
Boxrud, DJ ;
Li, ZY ;
Sakota, V ;
Thompson, TA ;
Facklam, RR ;
Besser, JM ;
Harrison, LH ;
Whitney, CG ;
Beall, B .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (09) :4194-4216
[4]   Invasive pneumococcal disease in Scotland, 1999-2001: Use of record linkage to explore associations between patients and disease in relation to future vaccination policy [J].
Kyaw, MH ;
Christie, P ;
Clarke, SC ;
Mooney, JD ;
Ahmed, S ;
Jones, IG ;
Campbell, H .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (10) :1283-1291
[5]   Prevalence of penicillin non-susceptible invasive pneumococcal disease in the elderly in Scotland, 1992-99 [J].
Kyaw, MH ;
Jones, IG ;
Campbell, H .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2002, 34 (08) :559-563
[6]   Incidence of invasive pneumococcal disease in Scotland, 1988-99 [J].
Kyaw, MH ;
Clarke, S ;
Jones, IG ;
Campbell, H .
EPIDEMIOLOGY AND INFECTION, 2002, 128 (02) :139-147
[7]   Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies [J].
Kyaw, MH ;
Clarke, S ;
Edwards, GFS ;
Jones, IG ;
Campbell, H .
EPIDEMIOLOGY AND INFECTION, 2000, 125 (03) :561-572
[8]   Pneumococcal disease in childhood [J].
Mohan, PV ;
Heath, PT .
HOSPITAL MEDICINE, 2001, 62 (07) :406-409
[9]  
Mühlemann K, 2003, J INFECT DIS, V187, P589, DOI 10.1086/367994
[10]   The pneumococcus: carriage, disease and conjugate vaccines [J].
Obaro, S ;
Adegbola, R .
JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 51 (02) :98-104